Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- cardiac
- Therapeutic
- Disease
- Pharmaceuticals
- Enzymes
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 243472
License Grant
The Licensor of Japan grants an exclusive, even as to Licensor, license, including the right to grant sublicenses, under the Licensors Intellectual Property to research, develop, make, have made, use, offer for sale, market, sell, import, export and distribute Compound and/or Product in and throughout the Licensee Territory in the Field.
License Property
The technology is a new chemical class of compounds of integrin alpha Vbeta3 and GPIIbIIIa receptors dual antagonists, including a lead compound known as CP4715, having potential cardio and cerebroprotective activity.
Product shall mean any pharmaceutical composition containing Compound as an active ingredient, in any formulation, delivery system or package configuration.
Compound shall mean the chemical compound, having dual antagonistic activity against both integrin alpha Vbeta3 and GPilbllla receptors which activity substantially contributes to the therapeutic efficacy for its intended use, which is the compound defined as (2S)-benzenesulfonylamino-3-[3-methoxy-4-{4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid and designated by the Licensor internal code name of CP4715.
MN-447 and MN-462 are antithrombic (anti-clotting) agents that represent novel approaches to blood clot formation and lysis, respectively, and are expected to treat a variety of thrombotic disorders.
MN-447 is a novel cardioprotective, anti-platelet agent that acts as a potent dual antagonist of glycoprotein (GP) IIbIIIa and integrin alpha-v-beta-3 receptors that play key roles in blood clot formation and various cell behaviors and functions such as leukocyte adhesion. MN-447 acts downstream by inhibiting the final common pathway of platelet aggregation — the cross-linking of platelets via fibrinogen bridges to GP IIbIIIa receptors. Inhibition of integrin alpha-v-beta-3 receptors has been linked to an inhibition of leukocyte adhesion to endothelium (the layer of cells lining blood vessels), reduction of hyperplasia (abnormal cellular proliferation) and lumen stenosis (blood vessel constriction) in response to vascular injury. In animal models of myocardial infarction and unstable angina, the dual inhibitory activity of MN-447 produced superior cardioprotective efficacy, such as reduction in infarct size after reperfusion (restoration of blood flow), compared to inhibition of the GP IIbIIIa receptor alone and showed a low risk of bleeding.
MN-462 is a selective inhibitor of a key enzyme in the intrinsic antifibrinolytic mechanism, plasma carboxypeptidase B (CPB; also called activated thrombin-activatable fibrinolysis inhibitor (TAFIa)), which inhibits physiological fibrinolysis (the lysis or dissolving of blood clots). By enhancing intrinsic fibrinolysis through plasma CPB inhibition, MN-462 has the potential to both reduce and prevent thrombus or blood clot formation as well as to dissolve formed thrombus, and consequently, represents a novel approach to treating various thrombotic disorders. In preclinical studies, MN-462 has demonstrated significant fibrinolytic-enhancing and anti-thrombotic activities as monotherapy in several thrombosis models, as well as activities when used as an adjunct to fibrinolytics such as tissue plasminogen activator (t-PA). The effect of MN-462 in enhancing the intrinsic fibrinolytic process has also been observed to result in a low risk of bleeding.
Field of Use
The Field shall mean any use of Compound or Product in humans. The patent application includes human platelet aggregation inhibitory activity, and, therapeutic agents for treating cardiovascular diseases, angiogenesis-related diseases, cerebrovascular diseases and the like and for inhibiting platelet aggregation.
IPSCIO Record ID: 243473
License Grant
The Licensor of Japan grants an exclusive, even as to Licensor, license, including the right to grant sublicenses, under the Licensor Intellectual Property to research, develop, make, have made, use, offer for sale, market, sell, import, export and distribute Compound and/or Product in and throughout the Licensee Territory in the Field.
License Property
The Licensor has a new chemical class of compounds of plasma carboxypeptidase B inhibitor, including lead compounds known as EF6265 and EF6243, having potential fibrinolysis enhancing and antithrombotic activity.
Product shall mean any pharmaceutical composition containing Compound as an active ingredient, in any formulation, delivery system or package configuration.
Compound shall mean the chemical compound,[having inhibitory activity against plasma carboxypeptidase B (also known as activated thrombin-activatable fibrinolysis inhibitor) which activity substantially contributes to the therapeutic efficacy for its intended use, which is the compounds defined as (S)-7-Amino-2-[[[(R)-2-methyl-1-(3- phenylpropanoylamino) propyl]hydroxyphosphinoyl]methyl] heptanoic acid and designated by the MS internal code name of EF6265 and (S)-7-Amino-2-[[[(R)-2-methyl-1- (3-phenylpropanoylamino) propyl]hydroxyphosphinoyl]oxy] heptanoic acid and designated by the MS internal code name of EF6243].
Field of Use
The Field shall mean any use of Compound or Product in humans. The patent application includes for therapeutic and preventive treatment of various thrombosis, diseases caused by a vascular disorder, and organ disorders resulting from reduction of fibrinolysis.
Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. The primary type is a normal body process, whereas secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause.
IPSCIO Record ID: 368507
License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.
U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.
Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.
Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).
IPSCIO Record ID: 5786
License Grant
The University's Technology Transfer & Commercialization Office hereby grants to Licensee a License subject to the terms and conditions hereof, in the territory and in the field.
License Property
Therapeutic applications of Non-PESDA (Non-perfluorocarbon enhanced sonicated dextrose albumin) microbubbles for the treatment of thrombosis, as described in UNMC Docket Series 63095. Intellectual property relates to thrombolytic agents and methods of treating thrombosis.
Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel is injured, the body uses platelets and fibrin to form a blood clot, because the first step in repairing it (hemostasis) is to prevent loss of blood. Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.
Field of Use
Field Therapeutic applications of Non-PESDA (Non-perfluorocarbon enhanced sonicated dextrose albumin) microbubbles for the treatment of thrombosis, as described in UNMC Docket Series 63095.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system.
IPSCIO Record ID: 372578
License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.
This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.
License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.
CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.
Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.
Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI. Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks. Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
IPSCIO Record ID: 2719
License Grant
Seller shall sell, transfer, assign, convey, deliver, license or sublicense, as specified below, to Buyer, or shall cause to be sold, transferred, assigned, conveyed, delivered, licensed or sublicensed, as specified below, to Buyer, and Buyer shall acquire all of Seller’s right, title and interest in and to the properties and assets of Seller.
Field of Use
The Licensee would acquire all rights to the cardiovascular products, including related trademarks, patents, intellectual property, product inventory and other related assets consisting of Cardene® I.V. (nicardipine hydrochloride), Cardene SR® and new formulations of Cardene in development, as well as Retavase® (reteplase) and the development product ularitide. Cardene® is for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene I.V. is the only intravenous calcium channel blocker (calcium ion influx inhibitor) for this indication. Cardene I.V. offers rapid, precise blood pressure control and has been proven to be as effective as sodium nitroprusside with fewer dose adjustments (1). Cardene I.V. prevents calcium ions from entering cardiac and vascular smooth muscle cells (the cells that line the arteries) through specific ion channels in the cell membrane. When these channels are blocked, calcium cannot enter the cell, thereby preventing the vascular smooth muscle from contracting. Retavase® (reteplase) is a fibrinolytic agent for the management of acute myocardial infarction (AMI) or heart attack in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment. Retavase, a recombinant plasminogen activator, works by generating plasmin, an enzyme produced naturally by the body’s blood plasma. Plasmin breaks down fibrin, a major constituent of blood clots, thereby helping to dissolve the clots.
IPSCIO Record ID: 240469
License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised. This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
